Human growth hormone available for AIDS wasting. [news] Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Human growth hormone available for AIDS wasting. [news] Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Treat Issues. 1995 Jan;9(1):9-11. Unique Identifier : AIDSLINE AIDS/95700118
Gilden D

Abstract: The Food and Drug Administration has approved a treatment IND allowing Serono Laboratories to distribute its experimental version of human growth hormone (HGH) to people with AIDS-related wasting syndrome. To receive HGH, a person with AIDS must have lost 10 percent of normal body weight without apparent cause, and must have first tried the appetite stimulants Megace and Marinol. HGH reorients the body's metabolism so that is focuses on rebuilding protein stores that are lost from lean tissue mass during the course of the disease. Wasting can be either acute and caused by a specific gastrointestinal or other infection, or chronic and non- specific. The treatment IND covers 12 weeks of therapy during which physicians will examine their patients 4 times and collect basic safety data for Serono. Patients can be reenrolled for an additional 12 weeks if a need for HGH remains. Patients or third- party payers will have to reimburse doctors for data collection and paper work costs, and will pay $25 per mg (a daily dose is 6 mg). This cost recovery is a precedent-setting aspect of Serono's treatment IND.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/*PHYSIOPATHOLOGY Body Weight Drugs, Investigational/THERAPEUTIC USE Fees, Pharmaceutical Human Somatotropin/*THERAPEUTIC USE NEWSLETTER ARTICLE NEWSKWDacquiredimmunodeficiencysyndrome/complications/KWDphysiopathologybodyweightdrugs,investigational/therapeuticusefees,pharmaceuticalhumansomatotropin/KWDtherapeuticusenewsletterarticlenews
950530
M9551021

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .